SCHEMBL17035936

SCHEMBL17035936

CC(C)(C)OC(=O)NCc1cscn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.43
CTSK P43235 1/20 0.42
CA12 O43570 3/20 0.42
CA1 P00915 3/20 0.42
CA2 P00918 3/20 0.42
CA9 Q16790 3/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
KDM4C Q9H3R0 1/20 0.41
KDM4A O75164 1/20 0.41
PDE10A Q9Y233 1/20 0.40
SCN9A Q15858 1/20 0.39
NAMPT P43490 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GFER P55789 1/20 0.38
STK17B O94768 1/20 0.38
STK17A Q9UEE5 1/20 0.38
CACNA1H O95180 1/20 0.38
CACNA1B Q00975 1/20 0.38
CACNA1C Q13936 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28899641 0.87 HTT (0.44) CA12CA1CA2CA9TDP1
SCHEMBL21743811 0.87 MAOA (0.48) L3MBTL1CTSKCA12CA1CA2
SCHEMBL20571809 0.84 TDP1 (0.47) CA12CA1CA2CA9LMNA
SCHEMBL17038776 0.83 PDE10A (0.45) CTSKKDM4ELMNAKDM4CPDE10A
SCHEMBL12265803 0.79 KDM4C (0.43) CTSKCA1CA2KDM4ELMNA
SCHEMBL6730949 0.79 SCN9A (0.46) CTSKCA1CA2CA9SCN9A
SCHEMBL30101880 0.78 CCR5 (0.41) LMNA
SCHEMBL30101991 0.78 CCR5 (0.41) LMNA
SCHEMBL8216843 0.78 L3MBTL1 (0.50) L3MBTL1CA1CA2NAMPTTDP1
SCHEMBL31625175 0.78 L3MBTL1 (0.43) L3MBTL1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170298085-A1 CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2017-10-19 US disclosed
US-20170298085-A1 CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2017-10-19 US disclosed
US-9732103-B2 Carbamate, ester, and ketone compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-08-15 US disclosed
US-9732103-B2 Carbamate, ester, and ketone compounds for treatment of complement mediated disorders ACHILLION PHARMACEUTICALS, INC. (US) 2017-08-15 US disclosed
US-20150239919-A1 Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders ACHILLION PHARMACEUTICALS, INC. (US) 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298085-A1 CARBAMATE, ESTER, AND KETONE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS CFD, C9, CFH L3MBTL1 1693/4885CTSK 495/4885CA12 262/4885
US-20150239919-A1 Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders CFD, C9, CFH L3MBTL1 1693/4885CTSK 495/4885CA12 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.